Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

354,475 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/02/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/02/2020.
Displaying: 2,295 trials in your specialties ()
View trials across your selected specialties

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small ...
View Full Trial
INTERVENTION

Drug: Cisplatin, Drug: Docetaxel, Drug: Erlotinib, Drug: Erlotinib Hydrochloride, Other: Laboratory Biomarker Analysis

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

M D Anderson Cancer Center, Houston, Texas, United States

Brief Summary

This phase I trial studies docetaxel, cisplatin, and erlotinib hydrochloride in treating patients with stage I-III non-small cell lung cancer following surgery. Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving docetaxel, cisplatin, and erlotinib hydrochloride together may kill more tumor cells.

Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Neuroblastoma
View Full Trial
INTERVENTION

Biological: EBV specific CTLs

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Texas Children's Hospital, Houston, Texas, United States

Brief Summary

Patients have high-risk neuroblastoma, a form of cancer typically found in children. The patients previously participated in a gene transfer research study using special immune cells. This research study combines two different ways of fighting disease, antibodies and T cells. Antibodies are types of proteins that protect the body from bacterial and other infections. T cells, also called cytotoxic T lymphocytes or CTLs, are special infection-fighting blood cells that can kill some tumor cells. Both antibodies and T cells have been used to treat patients with cancers and while they have shown promise, they have not been strong enough to cure most patients. The antibody used in this study is called 14g2a. This antibody sticks to neuroblastoma cells because of a substance on the outside of these cells called GD2. 14g2a and other antibodies that bind to GD2 have been used to treat people with neuroblastoma. For this study 14g2a has been changed so that instead of floating free in the blood, it is now joined to T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. T lymphocytes or CTLs can kill tumor cells but there normally are not enough of them to kill all tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the patient. Sometimes an antibody or chimeric receptor is attached to these T cells to help them bind to tumor cells. These chimeric receptor-T cells seem to kill some of the tumor, but they don't last very long in the body and so the tumor eventually comes back. We have found that T cells that are also trained to recognize the virus that causes infectious mononucleosis, Epstein Barr Virus (EBV), can stay in the blood stream for many years. By joining the 14g2a antibody to the CTLs that recognize EBV, we believe we will make a cell that can last a long time in the body (because they are EBV-specific) and recognize and kill neuroblastoma cells (because an antibody that can recognize these cells has been placed on their surface). Patients received treatment with the immune cells described above. They may want to receive an additional dose of these cells. This is being offered as an option because their neuroblastoma has returned and they have enough cells remaining to provide the patients with an additional dose. These 14g2a antibody CTLs are an investigational product not approved by the Food and Drug Administration.

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Neoplasm R...
View Full Trial
INTERVENTION

Drug: Rhenium (Re 188 P2045, BAY86-5284)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Iowa City, Iowa, United States

Brief Summary

The purpose of this study is to determine the maximum dose that is safely tolerated of the experimental drug Rhenium Re 188 P2045. This will be done by first treating patients at relatively low doses of Rhenium Re 188 P2045, observing them closely to assure that there are no bad side effects, then increasing the dose when we are confident that it is safe to do so.

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Leukemia, Acute Lymphoblastic Leukemia
View Full Trial
INTERVENTION

Biological: gene-modified T cells targeted

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Brief Summary

This study is an investigational approach that uses immune cells, called "T cells", to kill leukemia. These T cells are removed from blood, modified in a laboratory, and then put back in the body. T cells fight infections and can also kill cancer cells in some cases. However, right now T cells are unable to kill the cancer cells. For this reason we will put one gene into the T cells that allows them to recognize and kill the leukemia cells. This gene will be put in the T cells by a weakened virus. The gene will produce proteins in the T cells that help the T cells recognize the leukemia cells and possibly kill them. The doctors have found that T cells modified in this way can cure an ALL-like cancer in mice. The main goals of this study is to determine the safety and appropriate dose of these modified T cells in patients with ALL. This will be done in a "clinical trial." The dose of modified T-cells will depend on if you have disease present in your bone marrow or not. The patient will also receive chemotherapy before the T cells. We will use normally chemotherapy that is used in patients with leukemia. The chemotherapy is given to reduce leukemia and to allow the T cells to live longer.

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Carcinoma
View Full Trial
INTERVENTION

Drug: Intraperitoneal Oxaliplatin, Drug: Bevacizumab, Drug: Capecitabine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Washington University School of Medicine, Saint Louis, Missouri, United States

Brief Summary

This study is to test escalating doses of intraperitoneal (IP) oxaliplatin in conjunction with systemic bevacizumab and capecitabine in patients with Peritoneal Carcinomatosis (PC) from either appendiceal or colorectal adenocarcinoma that have been adequately cytoreduced and have undergone a peritoneal scan demonstrating patency of at least one of the intraperitoneal ports that were placed at the time of debulking.

Safety Study of MGAH22 in HER2-positive Carcinomas

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Breast Cancer, Gastric Cancer
View Full Trial
INTERVENTION

Biological: MGAH22

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

National Cancer Institute, Bethesda, Maryland, United States

Brief Summary

The purpose of this study is to determine if MGAH22 is safe when given by intravenous (IV) infusion to patients with HER2-positive cancer. The study will also evaluate how long MGAH22 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it has an effect on tumors.

Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Batten Disease, Late-Infantile Neuronal Ceroid Lipofuscinosis
View Full Trial
INTERVENTION

Biological: AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies, Biological: AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Weill Cornell Medical College, New York, New York, United States

Brief Summary

This is a proposed follow up study on the investigators previous gene transfer human clinical trial entitled "Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human CLN2 cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis" (Weill Cornell IRB# 0401007010). As in the previous study, the investigators propose to administer a biologic by direct gene transfer into the brain and assess its safety on children with a fatal genetic disease of the central nervous system (CNS). The disease is Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL, a form of Batten disease). This will be accomplished by using delivery of a gene (method called gene transfer) to administer to the brain an experimental drug called AAVRh.10CUhCLN2, a gene transfer vector.

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Solid Tumors, Advanced Cancer
View Full Trial
INTERVENTION

Drug: Anastrozole, Drug: Bevacizumab, Drug: Everolimus, Drug: Sorafenib, Drug: Erlotinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Brief Summary

The goal of this clinical research study to find the highest tolerated dose of anastrozole alone or in combination with either everolimus (Afinitor), sorafenib (Nexavar), erlotinib (Tarceva), fulvestrant (Faslodex), or bevacizumab (Avastin) that can be given to patients with advanced cancer. The safety of these drug combinations will also be studied.

Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Lymphoplasmacytic Lymphoma
View Full Trial
INTERVENTION

Biological: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine, Other: Laboratory Biomarker Analysis

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

M D Anderson Cancer Center, Houston, Texas, United States

Brief Summary

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with lymphoplasmacytic lymphoma. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells.

Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Peritoneal Cancer
View Full Trial
INTERVENTION

Biological: 131 I-8H9

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Brief Summary

The purpose of this study is to test the safety of a new medicine called antibody 8H9 injected into the lining of the abdomen or peritoneum, where the tumor is. This medicine is an antibody or protein which binds to certain tumors, including DSCRT. There is a small number of DSCRT which do not bind with 8H9. If the tumor does not bind with 8H9, you might not benefit from this treatment. The investigators want to find out what effects, good and/or bad, it has. This antibody is made in mice. Radioactive iodine can be bound to this antibody to deliver radiation to the tumor. The investigators wish to determine the safety of radiolabeled 8H9 at different dose levels. This is the first study using 131I-8H9 in the peritoneum.